参考文献/References:
[1] 胡盛寿,王增武. 《中国心血管健康与疾病报告2022》概述[J]. 中国心血管病研究,2023,21(7):577-600.
[2] Wang JG,Zhang W,Li Y,et al. Hypertension in China:epidemiology and treatment initiatives[J]. Nat Rev Cardiol,2023,20(8):531-545.
[3] Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J]. Lancet,2009,373(9671):1275-1281.
[4] Esler MD,Krum H,Sobotka PA,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial):a randomised controlled trial[J]. Lancet,2010,376(9756):1903-1909.
[5] Bhatt DL,Kandzari DE,O’Neill WW,et al. A controlled trial of renal denervation for resistant hypertension[J]. N Engl J Med,2014,370(15):1393-1401.
[6] Kario K,Ogawa H,Okumura K,et al. SYMPLICITY HTN-Japan—First randomized controlled trial of catheter-based renal denervation in Asian patients—[J]. Circ J,2015,79(6):1222-1229.
[7] Azizi M,Sapoval M,Gosse P,et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN):a multicentre,open-label,randomised controlled trial[J]. Lancet,2015,385(9981):1957-1965.
[8] Desch S,Okon T,Heinemann D,et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension[J]. Hypertension,2015,65(6):1202-1208.
[9] Mathiassen ON,Vase H,Bech JN,et al. Renal denervation in treatment-resistant essential hypertension. A randomized,SHAM-controlled,double-blinded 24-h blood pressure-based trial[J]. J Hypertens,2016,34(8):1639-1647.
[10] de Jager RL,de Beus E,Beeftink MM,et al. Impact of medication adherence on the effect of renal denervation:the SYMPATHY trial[J]. Hypertension,2017,69(4):678-684.
[11] Warchol-Celinska E,Prejbisz A,Kadziela J,et al. Renal denervation in resistant hypertension and obstructive sleep apnea:randomized proof-of-concept phase Ⅱtrial[J]. Hypertension,2018,72(2):381-390.
[12] Townsend RR,Mahfoud F,Kandzari DE,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED):a randomised, sham-controlled,proof-of-concept trial[J]. Lancet,2017,390(10108):2160-2170.
[13] Kandzari DE,B?hm M,Mahfoud F,et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial[J]. Lancet,2018,391(10137):2346-2355.
[14] Mahfoud F,Kandzari DE,Kario K,et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED):a randomised,sham-controlled trial[J]. Lancet,2022,399(10333):1401-1410.
[15] Azizi M,Schmieder RE,Mahfoud F,et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO):a multicentre,international,single-blind,randomised,sham-controlled trial[J]. Lancet,2018,391(10137):2335-2345.
[16] Wang J,Yin Y,Lu C,et al. Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART):6-month follow-up of a randomised,controlled trial[J]. EClinicalMedicine,2024,72:102626.
[17] 李月平,卢成志,蒋雄京,等. 经皮去肾神经术治疗高血压中国专家科学声明[J]. 中国介入心脏病学杂志,2023,31(12):881-893.
[18] Barbato E,Azizi M,Schmieder RE,et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J]. Eur Heart J,2023,44(15):1313-1330.
[19] Mancia G,Kreutz R,Brunstr?m M,et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension:Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)[J]. J Hypertens,2023,41(12):1874-2071.
[20] Guber K,Kirtane AJ. Renal sympathetic denervation for hypertension[J]. Kidney Int Rep,2022,7(10):2129-2140.
[21] 蒋雄京,姜凯文,贾楠,等. 当前经导管去肾神经术治疗高血压技术面面观——临床研究结果与存在的问题[J]. 中国循环杂志,2023,38(10):999-1004.
[22] Mahfoud F,Mancia G,Schmieder RE,et al. Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range[J]. J Am Coll Cardiol,2022,80(20):1871-1880.
[23] Kordalis A,Tsiachris D,Pietri P,et al. Regression of organ damage following renal denervation in resistant hypertension:a meta-analysis[J]. J Hypertens,2018,36(8):1614-1621.
[24] Wang L,Li C,Li Z,et al. Ten-year follow-up of very-high risk hypertensive patients undergoing renal sympathetic denervation[J]. J Hypertens,2024,42(5):801-808.
[25] Wang TD,Lee YH,Chang SS,et al. 2019 Consensus Statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on renal denervation for the management of arterial hypertension[J]. Acta Cardiol Sin,2019,35(3):199-230.
[26] Saxena M,Schmieder RE,Kirtane AJ,et al. Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study[J]. J Hum Hypertens,2022,36(7):629-639.
[27] Gosse P,Cremer A,Kirtane AJ,et al. Ambulatory blood pressure monitoring to predict response to renal denervation:a post hoc analysis of the RADIANCE-HTN SOLO study[J]. Hypertension,2021,77(2):529-536.
[28] Rohla M,Nahler A,Lambert T,et al. Predictors of response to renal denervation for resistant arterial hypertension:a single center experience[J]. J Hypertens,2016,34(1):123-129.
[29] Tsioufis C,Papademetriou V,Dimitriadis K,et al. Catheter-based renal sympathetic denervation exerts acute and chronic effects on renal hemodynamics in swine[J]. Int J Cardiol,2013,168(2):987-992.
[30] D?r O,Liebetrau C,M?llmann H,et al. Brain-derived neurotrophic factor as a marker for immediate assessment of the success of renal sympathetic denervation[J]. J Am Coll Cardiol,2015,65(11):1151-1153.
[31] de Jong MR,Adiyaman A,Gal P,et al. Renal nerve stimulation-induced blood pressure changes predict ambulatory blood pressure response after renal denervation[J]. Hypertension,2016,68(3):707-714.
[32] Honton B,Pathak A,Sauguet A,et al. First report of transradial renal denervation with the dedicated radiofrequency Iberis? catheter[J]. EuroIntervention,2014,9(12):1385-1388.
[33] Fengler K,Rommel KP,Blazek S,et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN)[J]. Circulation,2019,139(5):590-600.
[34] Chowdhury EK,Reid CM,Zomer E,et al. Cost-effectiveness of renal denervation therapy for treatment-resistant hypertension:a best case scenario[J]. Am J Hypertens,2018,31(10):1156-1163.
[35] Sharp ASP,Cao KN,Esler MD,et al. Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension:an analysis for the UK based on recent clinical evidence[J]. Eur Heart J Qual Care Clin Outcomes,2024:qcae001.
[36] Bermpeis K,Ohashi H,Bertolone DT,et al. First-in-man robotic-assisted renal?denervation[J]. JACC Case Rep,2022,4(23):101669.
[37] Kandzari DE,Mahfoud F,Weber MA,et al. Clinical trial design principles and outcomes definitions for device-based therapies for hypertension:a consensus document from the Hypertension Academic Research Consortium[J]. Circulation,2022,145(11):847-863.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(10):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(10):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(10):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(10):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(10):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(10):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(10):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
[11]陈晓平,左祥浩,叶涛,等.当前经导管去肾神经术治疗高血压面临的挑战[J].心血管病学进展,2024,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.002]
CHEN Xiaoping,ZUO Xianghao,YE Tao,et al.Current Challenges of Transcatheter Renal Denervation in the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2024,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.002]
[12]亢园园 罗淞元 许建忠 罗建方 卢成志.当前不同去肾神经术的特点和存在的问题[J].心血管病学进展,2024,(10):875.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.003]
KANG yuanyuan,LUO Songyuan,XU Jianzhong,et al.The Mechanisms and Future Challenges of Different Renal Denervation Therapy[J].Advances in Cardiovascular Diseases,2024,(10):875.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.003]
[13]王沛坚 陈威 董徽 马为.中国自主研发RDN器械治疗高血压临床试验数据的特色[J].心血管病学进展,2024,(10):880.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.004]
WANG Peijian,CHEN Wei,DONG Hui,et al.Characteristics of Clinical Trial Data of RDN Devices Independently Developed in China[J].Advances in Cardiovascular Diseases,2024,(10):880.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.004]
[14]封欣妤 张冬颖 邹玉宝 冯颖青 程康.如何选择去肾神经术治疗高血压的最适宜人群[J].心血管病学进展,2024,(10):885.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.005]
FENG Xinyu,ZHANG Dongying,ZOU Yubao,et al.How to Select the Optimal Population for Renal Denervation in the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2024,(10):885.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.005]
[15]董一飞 张毅 李燕 贾楠.经皮去肾神经术治疗高血压的临床获益：证据和争议[J].心血管病学进展,2024,(10):890.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.006]
DONG Yifei,ZHANG Yi,LI Yan,et al.Clinical Benefit of Renal Denervation In the Treatment of Hypertension:Evidence And Controversy[J].Advances in Cardiovascular Diseases,2024,(10):890.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.006]